May 9, 2018 / 7:11 AM / 3 months ago

BRIEF-Biohaven Initiates Expanded Access Program For Sublingual BHV-0223

May 9 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN INITIATES EXPANDED ACCESS PROGRAM FOR SUBLINGUAL BHV-0223 ZYDIS ORALLY DISSOLVING TABLETS FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS

* BIOHAVEN PHARMACEUTICAL HOLDING CO - ANTICIPATES SUBMITTING A NEW DRUG APPLICATION FOR BHV-0223 TO U.S. FOOD AND DRUG ADMINISTRATION IN Q3 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below